Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B

Cancer. 1991 Oct 15;68(8):1696-8. doi: 10.1002/1097-0142(19911015)68:8<1696::aid-cncr2820680807>3.0.co;2-b.

Abstract

Forty-four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life-threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Cisplatin / administration & dosage
  • Cytarabine / administration & dosage
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Middle Aged
  • Prospective Studies
  • Survival Rate

Substances

  • Cytarabine
  • Cisplatin